EMEA/APAC: Wednesday, 1:00 p.m. CET – 26 June 2024
NA/LATAM: Thursday, 10:00 a.m. EDT – 27 June 2024
This is the first in a series of continuous manufacturing webinars, we will cover thermal binders that enable melt granulation of immediate-release and controlled-release oral solid dosage formulations.
Pharmaceutical companies are prioritizing the implementation of continuous manufacturing (CM) while striving to reduce their environmental impact and achieve their ESG targets. The need to improve manufacturing efficiency, reduce production costs, and reduce environmental impact is influencing the industry’s manufacturing techniques. We are taking this opportunity to evaluate advances in granulation methods and demonstrate how those advances can be leveraged to achieve the abovementioned goals of the industry.
When implementing continuous manufacturing, pharmaceutical formulators have often utilized the same granulation technique used in batch manufacturing, leading to the continued dominance of wet granulation and underutilization of melt granulation technologies.
The advent of functional excipients optimized for melt granulation can enable the broader adoption of continuous manufacturing and the ESG benefits to be achieved.
Melt granulation has less inherent environmental impact than wet granulation, as no water is required, thus reducing water consumption. No drying step is required, reducing energy consumption. The elimination of the drying step and the improved performance of new thermal binders have also been shown to reduce overall processing time.
Along with the processing benefits, newer thermoplastic excipients have properties that may provide more stable formulations and more robust tablets and allow for the delivery of a broader range of APIs that were formerly too sensitive for melt granulation processes.
Join us and our pre-eminent guest speaker for webinar #1 in our continuous manufacturing series. We will cover thermal binders that enable melt granulation of immediate-release and controlled-release oral solid dosage formulations.
key learning objectives:
understand the benefits of melt granulation versus alternative CM methods (direct compression, roller compaction, wet granulation)
gain insight into the critical material attributes of excipients optimized for melt granulation and their role in addressing tabletability and product stability challenges
understand how to select appropriate excipients and optimize twin-screw melt granulation for immediate and controlled release formulations.
overview of enabling technologies: klucel™ xtend hpc, klucel fusion™ hpc
presenter information:
Dr. Thomas Dürig
Head of Life Sciences R&D, Ashland
Tom Dürig serves as senior director, Life Sciences R&D at Ashland where he has global responsibility for the Life Sciences R&D function. He has over 20 years’ experience in a variety of settings, including R&D, GMP manufacturing at major multi-national corporations and in academia. Tom is internationally recognized for his sustained professional excellence and contribution to the pharmaceutical and nutraceutical sciences in the fields of solid dosage form and delivery system design, excipient technologies and particle and polymer engineering. He holds several patents pertaining to pharmaceutical and nutritional additives, advanced dosage form design and has co-authored over 130 publications, book chapters and conference presentations on these topics.
Dr. Feng Zhang
Associate Professor Division of Molecular Pharmaceutics and Drug Delivery, University of Texas at Austin
Feng Zhang is an associate professor at the Division of Molecular Pharmaceutics and Drug Delivery at the University of Texas at Austin. He received his Ph.D. in pharmaceutics from the University of Texas at Austin. He worked in the industry for 14 years prior to joining the department of pharmaceutics at the University of Texas at Austin in 2014. He was the Director of Product Development at PharmaForm (now part of BioDuro) from 2007 to 2010 and Senior Scientist in the Formulation and Process development department at Gilead from 2011 to 2013. Zhang has been conducting research and product development using twin-screw extrusion process since 1994. His principal research interest at UT Austin is in twin-screw extrusion processing of granules for tablets and capsules, amorphous solid dispersions for bioavailability enhancement, and long-acting implants. He is the editor of 2nd edition of “Pharmaceutical Extrusion Technology”, published in 2018. He has authored four book chapters on twin-screw extrusion process. He has published 60 peer-reviewed papers articles. He is also inventor on 12 issued patents covering a wide range of drug delivery systems. He serves on the editorial board of AAPS PharmSci Tech and North American editor for Journal of Drug Delivery Science and Technology.
©, Ashland. All rights reserved.
